Back to Search
Start Over
PRS30 BUDGET IMPACT ANALYSIS OF A SINGLE-INHALER TRIPLE THERAPY (TRELEGYÃ') VERSUS DUAL COMBINATION AND MULTIPLE-INHALER TRIPLE THERAPY FOR THE TREATMENT OF PATIENTS WITH COPD MODERATE TO VERY-SEVERE FROM PUBLIC HEALTH SYSTEM PERSPECTIVE IN CHILE.
- Source :
-
Value in Health . 2020 Supplement 1, Vol. 23, pS354-S354. 1p. - Publication Year :
- 2020
-
Abstract
- PRS30 BUDGET IMPACT ANALYSIS OF A SINGLE-INHALER TRIPLE THERAPY (TRELEGYÃ') VERSUS DUAL COMBINATION AND MULTIPLE-INHALER TRIPLE THERAPY FOR THE TREATMENT OF PATIENTS WITH COPD MODERATE TO VERY-SEVERE FROM PUBLIC HEALTH SYSTEM PERSPECTIVE IN CHILE Determine the budget impact of give financial coverage to Trelegy (Fluticasone Furoate/Umeclidinium/Vilanterol in a single-inhaler triple therapy) versus Fluticasone Furoate/Vilanterol (FF/VIL), Umeclidinium/Vilanterol (UMEC/VI) and a multiple inhaler triple therapy which is Fluticasone Propionate 250mg/Salmeterol 25mg and tiotropium 18mcg (FP/SAL + TIO) in patients with COPD moderate to very-severe. The budget impact estimated for Trelegy over the five year versus FF/VIL was -MM$592.7, whilst Trelegy versus UMEC/VI and versus FP/SAL+TIO were estimated in -MM$50.7 and.MM$111.4, respectively. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 10983015
- Volume :
- 23
- Database :
- Academic Search Index
- Journal :
- Value in Health
- Publication Type :
- Academic Journal
- Accession number :
- 144265119
- Full Text :
- https://doi.org/10.1016/j.jval.2020.04.1352